Literature DB >> 7741004

Neomycin reduces the intestinal production of ammonia from glutamine.

R A Hawkins1, J Jessy, A M Mans, A Chedid, M R DeJoseph.   

Abstract

The mechanism by which neomycin treatment reduces circulating ammonia concentrations was studied in normal and portacaval shunted rats. Rats were given neomycin for 3 days and then fasted for 24 hours to eliminate feces. Neomycin decreased arteriovenous differences of ammonia across the intestine even when the intestines were empty. Neomycin treatment lowered the activity of glutaminase in the intestinal mucosa and the rate of ammonia production from glutamine by isolated intestinal segments. The intestines from portacaval shunted rats had higher glutaminase activity (by 57%), and produced ammonia from glutamine at a greater rate (by 31%), than intestines from controls. Neomycin treatment lowered glutaminase activity and ammonia production in shunted rats, but glutaminase activity still remained higher than in controls (by 23%). The data indicate that the mechanism by which neomycin lower plasma ammonia is owing, at least in part, to a direct effect on the intestines. Specifically, neomycin causes a reduction in mucosal glutaminase activity and thereby decreases the ability of the mucosa to consume glutamine and produce ammonia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7741004     DOI: 10.1007/978-1-4615-1989-8_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  15 in total

1.  Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration.

Authors:  M Plauth; A E Roske; P Romaniuk; E Roth; R Ziebig; H Lochs
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  Reduced stents and stent-grafts for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation.

Authors:  David C Madoff; Michael J Wallace
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

3.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 4.  The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists.

Authors:  Ponni V Perumalswami; Thomas D Schiano
Journal:  Dig Dis Sci       Date:  2011-03-18       Impact factor: 3.199

5.  Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress.

Authors:  Gangarao Davuluri; Allawy Allawy; Samjhana Thapaliya; Julie H Rennison; Dharmvir Singh; Avinash Kumar; Yana Sandlers; David R Van Wagoner; Chris A Flask; Charles Hoppel; Takhar Kasumov; Srinivasan Dasarathy
Journal:  J Physiol       Date:  2016-10-23       Impact factor: 5.182

Review 6.  Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy.

Authors:  Manuel Romero-Gómez
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

Review 7.  Hepatic Encephalopathy and Treatment Modalities: A Review Article.

Authors:  Kapil Sharma; Shivani Akre; Swarupa Chakole; Mayur B Wanjari
Journal:  Cureus       Date:  2022-08-14

Review 8.  Gut ammonia production and its modulation.

Authors:  Manuel Romero-Gómez; María Jover; J Jorge Galán; A Ruiz
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

9.  THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy.

Authors:  M Mar Díaz-Herrero; José A del Campo; Pilar Carbonero-Aguilar; José M Vega-Pérez; Fernando Iglesias-Guerra; Ignacio Periñán; Francisco J Miñano; Juan Bautista; Manuel Romero-Gómez
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

Review 10.  Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions.

Authors:  Duminda Suraweera; Vinay Sundaram; Sammy Saab
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.